

# Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024

August 1, 2024

GAITHERSBURG, Md., Aug. 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its second quarter 2024 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, August 8, 2024. Details of the event and replay are as follows:

Conference call details:

Date: August 8, 2024

Time: 8:30 a.m. U.S. ET

URL to register phone: <https://emportal.ink/3XTduSS>

Dial-in number: (800) 836-8184 (Domestic) or  
(+1) (646) 357-8785 (International)

Webcast: [ir.novavax.com/events](https://ir.novavax.com/events)

- *Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.*
- *Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.*
- *To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled webcast.*

Replay details:

Date: Available starting at 11:30 a.m. ET, August 8, 2024, until 11:59 p.m. U.S. ET, August 15, 2024

Dial-in number: (888) 660-6345 (Domestic) or  
(+1) (646) 517-4150 (International)

Passcode: 52500#

Webcast: [ir.novavax.com/events](https://ir.novavax.com/events), until September 8, 2024

## About Novavax

Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit [novavax.com](https://novavax.com) and [LinkedIn](#) for more information.

## Contacts:

### Investors

Erika Schultz  
240-268-2022

[ir@novavax.com](mailto:ir@novavax.com)

Media

Giovanna Chandler

202-709-5563

[media@novavax.com](mailto:media@novavax.com)

SOURCE Novavax, Inc.